Group 1 - The core viewpoint of the news is that Jianmin Group (600976) has shown a slight increase in stock price and has reported mixed financial results for the first quarter of 2025, with a decrease in total revenue but an increase in net profit [1][3] - As of July 31, 2025, Jianmin Group's stock closed at 41.65 yuan, up 0.95%, with a turnover rate of 2.41% and a trading volume of 37,000 hands, amounting to a transaction value of 153 million yuan [1] - The net inflow of main funds today was 13.82 million yuan, accounting for 9.01% of the transaction value, with significant contributions from large orders [1] Group 2 - For the first quarter of 2025, Jianmin Group reported total operating revenue of 892 million yuan, a year-on-year decrease of 8.04%, while net profit attributable to shareholders was 110 million yuan, a year-on-year increase of 10.70% [1] - The company has a current ratio of 1.646, a quick ratio of 1.456, and a debt-to-asset ratio of 40.15% [1] - Jianmin Pharmaceutical Group Co., Ltd. was established in 1993 and is primarily engaged in the pharmaceutical manufacturing industry, with a registered capital of 1.533986 billion yuan [1][2] Group 3 - Jianmin Pharmaceutical Group has made investments in 30 companies and participated in 5,000 bidding projects, indicating active engagement in the market [2] - The company holds 526 trademark registrations and 241 patent registrations, showcasing its focus on intellectual property [2] - Additionally, Jianmin Group possesses 313 administrative licenses, reflecting its compliance and operational capabilities [2]

Group 1 - The company announced the completion of its board of directors' re-election and senior management appointments on July 30 [1] - Yuan Pingdong was elected as the chairman of the 11th board of directors [1] - Wang Jun was reappointed as the president, while Huang Zhijun and Pei Xuejun were appointed as vice presidents [1] - Cheng Chaoyang was appointed as the financial director, Zhou Jie as the board secretary, and Cao Hong as the securities affairs representative [1]

Group 1 - The stock price of Jianmin Group closed at 41.26 yuan on July 30, 2025, with an increase of 0.21 yuan, representing a rise of 0.51% from the previous trading day [1] - The trading volume on that day was 168 million yuan, with a turnover rate of 2.64% [1] - Jianmin Group's main business includes pharmaceutical manufacturing and pharmaceutical commerce, with both segments contributing nearly 50% to the revenue in the 2024 financial report [1] Group 2 - On the evening of July 30, Jianmin Group announced several updates, including the completion of the 11th board of directors' re-election, the election of a new chairman, and the reappointment of CFO Cheng Chaoyang [1] - The company’s first extraordinary general meeting of shareholders in 2025 approved amendments to the company’s articles of association and other proposals [1]

Core Points - The company held its first meeting of the 11th Board of Directors on July 30, 2025, in Wuhan, with all 9 directors present, meeting legal requirements [1] - Yuan Pingdong was elected as the Chairman of the 11th Board of Directors, with unanimous support from all directors [1] - Wang Jun was reappointed as the President of the company, also receiving unanimous approval [2] - Huang Zhijun and Pei Xuejun were reappointed as Vice Presidents, with full agreement from the board [2] - Cheng Chaoyang was reappointed as the Chief Financial Officer, with unanimous support [3] - Zhou Jie was reappointed as the Board Secretary, and Cao Hong as the Securities Affairs Representative, both receiving unanimous approval [3] - The board approved the revision of 13 governance-related systems, adapting to the updated company charter approved at the 2025 first extraordinary general meeting [4] - The board authorized the office to make necessary adjustments to internal regulations, including changes in terminology related to supervisory roles [4]

Meeting Overview - The shareholders' meeting of Jianmin Pharmaceutical Group Co., Ltd. was held on July 30, 2025, in Wuhan [1] - The meeting was attended by shareholders representing 41.6122% of the total shares [1] - The meeting was presided over by the vice chairman of the board, Mr. Xu Liang, and followed legal procedures as per the Company Law and Articles of Association [1] Voting Results - All non-cumulative voting proposals were approved with significant majority support, with votes in favor ranging from 91.0178% to 99.9309% across various proposals [1][2] - Specific voting results included: - Proposal 1: 58,116,051 votes in favor (91.0444%) [1] - Proposal 2: 63,775,260 votes in favor (99.9101%) [1] - Proposal 3: 63,576,660 votes in favor (99.5990%) [2] Legal Confirmation - The meeting was legally validated by lawyers Lin Ling and Chen Lin, confirming that the meeting's convening, attendance, and voting procedures complied with the Articles of Association [3]

Core Points - The company has established an Audit Committee under the Board of Directors to enhance internal control and governance structure, in accordance with relevant laws and regulations [1][2][3] - The Audit Committee is responsible for reviewing financial information, supervising internal and external audits, and evaluating internal controls [3][4][5] - The committee consists of five members, including three independent directors, with at least one being a professional accountant [2][3][4] Group 1: Audit Committee Structure - The Audit Committee is composed of five directors who are not senior management, including three independent directors [2][3] - The committee is led by a chairperson who is an independent director with accounting expertise [2][3] - The term of the Audit Committee aligns with that of the Board of Directors, and members can be re-elected [2][3] Group 2: Responsibilities and Authority - The Audit Committee is tasked with reviewing financial reports, supervising audits, and ensuring compliance with laws and regulations [3][4][5] - It must approve significant financial disclosures and the hiring or dismissal of external auditors [3][4] - The committee is also responsible for monitoring internal audit activities and ensuring effective internal controls [4][5] Group 3: Operational Procedures - The Audit Committee meets at least quarterly, with additional meetings as needed, and requires a quorum of two-thirds of its members to proceed [6][10] - Meeting notifications must be sent at least two days in advance, and minutes must be recorded and maintained for ten years [10][12] - The committee can invite external experts for professional opinions as necessary [10][12]

关于选举第十一届董事会职工代表董事的公告 特此公告。 健民药业集团股份有限公司 董事会 二〇二五年七月三十一日 证券代码：600976 证券简称：健民集团 公告编号：2025-028 健民药业集团股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 根据健民药业集团股份有限公司（以下简称"公司"）2025 年第一次临时股东 大会审议通过的《公司章程（2025 修订稿）》，公司董事会成员中应至少有一名职 工代表，董事会中的职工代表董事由公司职工通过职工代表大会、职工大会、职代 会联席会或者其他形式民主选举产生。 波先生为公司第十一届董事会职工代表董事，任期自会议通过之日起至第十一届董 事会任期届满之日为止。胡振波先生简历详见附件。 胡振波先生与公司持股 5%以上的股东、实际控制人、公司其他董事、高级管理 人员不存在关联关系，未持有公司股票；胡振波先生具备担任公司董事的资格和能 力，不存在《中华人民共和国公司法》《上海证券交易所股票上市规则》《上海证 券交易所上市公司自律监管指引第 1 号——规范运作》和《公司章程》 ...

Core Viewpoint - The announcement details the completion of the board of directors' re-election and the appointment of senior management personnel at Jianmin Pharmaceutical Group Co., Ltd, highlighting the new board composition and management structure [1][2][3]. Board Re-election - The 11th board of directors consists of four non-independent directors: Mr. Wang Siyang, Mr. Yuan Pingdong, Mr. Wang Jun, and Mr. Xu Liang, along with three independent directors: Mr. Guo Yunpei, Mr. Yang Zhi, and Mr. Xin Jinguo, plus employee representative director Mr. Hu Zhenbo, serving a three-year term [1][2]. - Mr. Yuan Pingdong was elected as the chairman of the 11th board of directors [2]. Specialized Committees - The specialized committees of the board were established as follows: - Strategic and Sustainable Development Committee: Members include Yuan Pingdong, Guo Yunpei, Wang Siyang, Wang Jun, and Hu Zhenbo, with Yuan Pingdong as the convener [2]. - Audit Committee: Members include Xin Jinguo, Guo Yunpei, Yang Zhi, Pei Rong, and Xu Liang, with Xin Jinguo as the convener [2]. - Nomination Committee: Members include Guo Yunpei, Yang Zhi, Xin Jinguo, Wang Siyang, and Wang Jun, with Guo Yunpei as the convener [2]. - Compensation and Assessment Committee: Members include Yang Zhi, Guo Yunpei, Xin Jinguo, Yuan Pingdong, and Wang Siyang, with Yang Zhi as the convener [2]. - Independent directors constitute more than half of the audit, nomination, and compensation committees, with Xin Jinguo being a professional accountant [2]. Senior Management Appointments - Mr. Wang Jun was reappointed as the president of the company [2]. - Mr. Huang Zhijun and Mr. Pei Xuejun were reappointed as vice presidents [2]. - Mr. Cheng Chaoyang was reappointed as the financial director [2][3]. - Mr. Zhou Jie was reappointed as the board secretary, and Ms. Cao Hong was reappointed as the securities affairs representative [3]. Cancellation of Supervisory Board - The company will no longer have a supervisory board or supervisors, as approved by the 2025 first extraordinary shareholders' meeting and in accordance with relevant laws and regulations [4].

（文章来源：证券日报） 证券日报网讯 7月30日晚间，健民集团发布公告称，2025年7月30日，公司工会委员会及时召开了职代 会联席会，会议选举胡振波先生为公司第十一届董事会职工代表董事。 ...

Core Viewpoint - Jianmin Group announced the continued appointment of Mr. Cheng Zhaoyang as the Chief Financial Officer (CFO) of the company [2] Summary by Categories - **Company Announcement** - Jianmin Group released a notice on July 30, confirming the reappointment of Mr. Cheng Zhaoyang as the CFO [2]